All Stories

  1. Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models

    Article • Cancers, April 2019, MDPI AG

    Dr. Paola Perego

  2. Alterations of RNA Metabolism by Proteomic Analysis of Breast Cancer Cells Exposed to Marycin: A New Optically Active Porphyrin

    Article • Current Molecular Pharmacology, April 2019, Bentham Science Publishers

    Dr. Paola Perego, Elena Taverna, Maida De Bortoli

  3. Role of FoxO Proteins in Cellular Response to Antitumor Agents

    Article • Cancers, January 2019, MDPI AG

    Dr. Paola Perego

  4. KiSS1 in regulation of metastasis and response to antitumor drugs

    Article • Drug Resistance Updates, January 2019, Elsevier

    Dr. Paola Perego

  5. Tau Mutations as a Novel Risk Factor for Cancer—Response

    Article • Cancer Research, October 2018, American Association for Cancer Research (AACR)

    Dr. Paola Perego

  6. Tau mutations serve as a novel risk factor for cancer

    Article • Cancer Research, May 2018, American Association for Cancer Research (AACR)

    Dr. Paola Perego

  7. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models

    Article • Biochemical Pharmacology, January 2018, Elsevier

    Dr. Paola Perego

  8. Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group

    Article • Cancer Chemotherapy and Pharmacology, December 2017, Springer Science + Business Media

    Dr. Paola Perego

  9. Molecular basis for the DNA damage induction and anticancer activity of asymmetrically substituted anthrapyridazone PDZ-7

    Article • Oncotarget, October 2017, Impact Journals, LLC

    Prof. Joanna Wietrzyk, Dr. Paola Perego

  10. Editorial: Targeting Drug-resistant and Metastatic Tumors by Interference with Tumor and Microenvironment-related Alterations

    Article • Current Medicinal Chemistry, September 2017, Bentham Science Publishers

    Dr. Paola Perego

  11. Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells

    Article • Biochemical Pharmacology, July 2017, Elsevier

    Dr. Paola Perego

  12. Integrin-targeted peptide- and peptidomimetic-drug conjugates for the treatment of tumors

    Article • Recent Patents on Anti-Cancer Drug Discovery, February 2017, Bentham Science Publishers

    Dr Leonardo Manzoni, Dr. Paola Perego

  13. RECQL4 Modulates MDR1 Expression and Chemoresistance—Letter

    Article • Cancer Research, December 2016, American Association for Cancer Research (AACR)

    Dr. Paola Perego

  14. PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells

    Article • Toxicology and Applied Pharmacology, November 2016, Elsevier

    Dr. Paola Perego

  15. Synthetic sulfoglycolipids targeting the serine–threonine protein kinase Akt

    Article • Bioorganic & Medicinal Chemistry, August 2016, Elsevier

    Dr. Paola Perego

  16. Axl in the invasive capability and drug resistance of tumor cells

    Article • Current Medicinal Chemistry, May 2016, Bentham Science Publishers

    Dr. Paola Perego

  17. Targeting Peptidyl-Prolyl Isomerase Pin1 to Inhibit Tumor Cell Aggressiveness

    Article • Tumori Journal, March 2016, SAGE Publications

    Dr. Paola Perego

  18. Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy

    Article • Cancer Chemotherapy and Pharmacology, November 2015, Springer Science + Business Media

    Dr. Paola Perego

  19. Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis

    Article • Cancer Research, July 2015, American Association for Cancer Research (AACR)

    Dr. Paola Perego

  20. Orchestration of DSB repair: a novel BRCA2 connection

    Article • Cell Cycle, June 2015, Taylor & Francis

    Dr. Paola Perego

  21. New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants

    Article • Drug Resistance Updates, May 2015, Elsevier

    Dr. Paola Perego

  22. Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor

    Article • Biochemical Pharmacology, March 2015, Elsevier

    Dr. Paola Perego

  23. Anionic glycolipids related to glucuronosyldiacylglycerol inhibit protein kinase Akt

    Article • Organic & Biomolecular Chemistry, January 2015, Royal Society of Chemistry

    Dr. Paola Perego

  24. Design, synthesis and biological evaluation of novel dimeric and tetrameric cRGD–paclitaxel conjugates for integrin-assisted drug delivery

    Article • Organic & Biomolecular Chemistry, January 2015, Royal Society of Chemistry

    Dr Leonardo Manzoni, Dr. Paola Perego

  25. Preface: Histone Deacetylases as Therapeutic Targets

    Article • Critical Reviews™ in Oncogenesis, January 2015, Begell House

    Dr. Paola Perego

  26. p53-Dependent Activation of microRNA-34a in Response to Etoposide-Induced DNA Damage in Osteosarcoma Cell Lines Not Impaired by Dominant Negative p53 Expression

    Article • PLoS ONE, December 2014, PLOS

    Dr. Paola Perego

  27. Nucleolar Targeting by Platinum: p53-Independent Apoptosis Follows rRNA Inhibition, Cell-Cycle Arrest, and DNA Compaction

    Article • Molecular Pharmaceutics, December 2014, American Chemical Society (ACS)

    Dr. Paola Perego

  28. Association of promoter polymorphism −765G>C in the PTGS2 gene with malignant melanoma in Italian patients and its correlation to gene expression in dermal fibroblasts

    Article • Experimental Dermatology, September 2014, Wiley

    Dr. Paola Perego

  29. Phosphatidylinositol 3-Phosphate Mimics Based on a Sulfoquinovose Scaffold: Synthesis and Evaluation as Protein Kinase B Inhibitors

    Article • European Journal of Organic Chemistry, August 2014, Wiley

    Dr. Paola Perego

  30. Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells

    Article • Cancer Letters, June 2014, Elsevier

    Dr. Paola Perego

  31. Synergistic Cooperation Between Sunitinib and Cisplatin Promotes Apoptotic Cell Death in Human Medullary Thyroid Cancer

    Article • The Journal of Clinical Endocrinology & Metabolism, February 2014, Endocrine Society

    Dr. Paola Perego

  32. 7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors

    Article • Bioorganic & Medicinal Chemistry, February 2014, Elsevier

    Dr. Paola Perego

  33. Improved Apoptotic Cell Death in Drug-Resistant Non–Small-Cell Lung Cancer Cells by Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Based Treatment

    Article • Journal of Pharmacology and Experimental Therapeutics, December 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr. Paola Perego

  34. Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity

    Article • Cell Death and Disease, November 2013, Springer Science + Business Media

    Dr. Paola Perego

  35. Drug Combinations with Proteasome Inhibitors in Antitumor Therapy

    Article • Current Pharmaceutical Design, May 2013, Bentham Science Publishers

    Dr. Paola Perego

  36. Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells

    Article • Current Medicinal Chemistry, April 2013, Bentham Science Publishers

    Dr. Paola Perego

  37. Camptothecin Resistance in Cancer: Insights into the Molecular Mechanisms of a DNA-Damaging Drug

    Article • Current Medicinal Chemistry, March 2013, Bentham Science Publishers

    Dr. Paola Perego

  38. Synthesis and Biological Evaluation (in Vitro and in Vivo) of Cyclic Arginine–Glycine–Aspartate (RGD) Peptidomimetic–Paclitaxel Conjugates Targeting Integrin αVβ3

    Article • Journal of Medicinal Chemistry, November 2012, American Chemical Society (ACS)

    Dr. Paola Perego

  39. Homo- and heterodimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part I: Synthesis

    Article • Bioorganic & Medicinal Chemistry, November 2012, Elsevier

    Dr Leonardo Manzoni, Dr. Paola Perego

  40. Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization

    Article • Bioorganic & Medicinal Chemistry, November 2012, Elsevier

    Dr Leonardo Manzoni, Professor Martino Bolognesi, Dr. Paola Perego

  41. Design, Synthesis, and Biological Evaluation of Novel cRGD–Paclitaxel Conjugates for Integrin-Assisted Drug Delivery

    Article • Bioconjugate Chemistry, August 2012, American Chemical Society (ACS)

    Dr Leonardo Manzoni, Dr. Paola Perego

  42. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells

    Article • Journal of Inorganic Biochemistry, August 2012, Elsevier

    Dr. Paola Perego

  43. Sensitization of tumor cells by targeting histone deacetylases

    Article • Biochemical Pharmacology, April 2012, Elsevier

    Dr. Paola Perego

  44. Targeting DNA Topoisomerase I with Non-Camptothecin Poisons

    Article • Current Medicinal Chemistry, March 2012, Bentham Science Publishers

    Dr. Paola Perego

  45. Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition

    Article • Biochemical Pharmacology, January 2012, Elsevier

    Dr. Paola Perego

  46. Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032

    Article • Neoplasia, December 2011, Elsevier

    Dr. Paola Perego

  47. Inhibition of proteasome deubiquitinating activity as a new cancer therapy

    Article • Nature Reports Stem Cells, November 2011, Nature

    Professor Moustapha Hassan, Dr. Paola Perego

  48. Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy

    Article • Current Medicinal Chemistry, September 2011, Bentham Science Publishers

    Dr. Paola Perego

  49. Proteomic Analysis of Cellular Response to Novel Proapoptotic Agents Related to Atypical Retinoids in Human IGROV-1 Ovarian Carcinoma Cells

    Article • Journal of Proteome Research, March 2011, American Chemical Society (ACS)

    Dr. Paola Perego

  50. Ubiquitin-proteasome genes as targets for modulation of cisplatin sensitivity in fission yeast

    Article • BMC Genomics, January 2011, Springer Science + Business Media

    Dr. Paola Perego

  51. Heterogeneous Phenotype of Human Melanoma Cells with In Vitro and In Vivo Features of Tumor-Initiating Cells

    Article • Journal of Investigative Dermatology, July 2010, Elsevier

    Dr. Paola Perego

  52. Metabolic Approach to the Enhancement of Antitumor Effect of Chemotherapy: a Key Role of Acetyl-L-Carnitine

    Article • Clinical Cancer Research, June 2010, American Association for Cancer Research (AACR)

    Dr. Paola Perego

  53. The ABC of glycosylation

    Article • Nature Reviews Cancer, June 2010, Springer Science + Business Media

    Dr. Paola Perego

  54. Tyrosyl-DNA Phosphodiesterase 1 Targeting for Modulation of Camptothecin-Based Treatment

    Article • Current Medicinal Chemistry, May 2010, Bentham Science Publishers

    Dr. Paola Perego

  55. Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin

    Article • Biochemical Pharmacology, April 2010, Elsevier

    Dr. Paola Perego

  56. Ascites Regression and Survival Increase in Mice Bearing Advanced-stage Human Ovarian Carcinomas and Repeatedly Treated Intraperitoneally With CpG-ODN

    Article • Journal of Immunotherapy, January 2010, Wolters Kluwer Health

    Dr. Paola Perego

  57. Novel Bis-platinum Complexes Endowed with an Improved Pharmacological Profile

    Article • Molecular Pharmaceutics, November 2009, American Chemical Society (ACS)

    Dr. Paola Perego

  58. Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment

    Article • Proceedings of the National Academy of Sciences, September 2009, Proceedings of the National Academy of Sciences

    Dr. Paola Perego

  59. ABC Transporters as Potential Targets for Modulation of Drug Resistance

    Article • Mini-Reviews in Medicinal Chemistry, August 2009, Bentham Science Publishers

    Dr. Paola Perego

  60. Strategies to Improve the Efficacy of Platinum Compounds

    Article • Current Medicinal Chemistry, July 2009, Bentham Science Publishers

    Dr. Paola Perego

  61. A proteomic approach for evaluating the cell response to a novel histone deacetylase inhibitor in colon cancer cells

    Article • Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, November 2008, Elsevier

    Dr. Paola Perego

  62. Small Molecules Targeting p53 to Improve Antitumor Therapy

    Article • Mini-Reviews in Medicinal Chemistry, August 2008, Bentham Science Publishers

    Dr. Paola Perego

  63. Defining targets of modulation of human tumor cell response to cisplatin

    Article • Journal of Inorganic Biochemistry, July 2008, Elsevier

    Dr. Paola Perego

  64. Cooperation between p53 and p73 in cisplatin-induced apoptosis in ovarian carcinoma cells

    Article • Cancer Letters, May 2008, Elsevier

    Dr. Paola Perego

  65. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds

    Article • Molecular Cancer Therapeutics, March 2008, American Association for Cancer Research (AACR)

    Dr. Paola Perego

  66. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells

    Article • Cancer Letters, June 2007, Elsevier

    Dr. Paola Perego

  67. Biological Properties of IDN5174, a New Synthetic Camptothecin with the Open Lactone Ring

    Article • Cancer Research, November 2006, American Association for Cancer Research (AACR)

    Dr. Paola Perego

  68. Mechanisms of Cellular Resistance to Camptothecins

    Article • Current Medicinal Chemistry, November 2006, Bentham Science Publishers

    Dr. Paola Perego

  69. Modulation of cell growth and cisplatin sensitivity by membrane γ-glutamyltransferase in melanoma cells

    Article • European Journal of Cancer, October 2006, Elsevier

    Dr. Paola Perego

  70. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells

    Article • Biochemical Pharmacology, September 2006, Elsevier

    Dr. Paola Perego

  71. Cellular Sensitivity to β-Diketonato Complexes of Ruthenium(III), Chromium(III) and Rhodium(III)

    Article • Medicinal Chemistry, May 2006, Bentham Science Publishers

    Dr. Paola Perego

  72. Molecular alterations of cells resistant to platinum drugs: Role of PKCα

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, January 2006, Elsevier

    Dr. Paola Perego

  73. Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts

    Article • European Journal of Cancer, May 2005, Elsevier

    Dr. Paola Perego

  74. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431

    Article • PROTEOMICS, October 2004, Wiley

    Dr. Paola Perego

  75. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors

    Article • APOPTOSIS, September 2004, Springer Science + Business Media

    Dr. Paola Perego

  76. Global gene expression of fission yeast in response to cisplatin

    Article • Cellular and Molecular Life Sciences, August 2004, Springer Science + Business Media

    Professor Jurg Bahler, Dr. Paola Perego

  77. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells

    Article • Biochemical Pharmacology, July 2004, Elsevier

    Dr. Paola Perego

  78. γ-Glutamyl transpeptidase catalyses the extracellular detoxification of cisplatin in a human cell line derived from the proximal convoluted tubule of the kidney

    Article • European Journal of Cancer, May 2003, Elsevier

    Dr. Paola Perego

  79. Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models

    Article • Biochemical Pharmacology, April 2003, Elsevier

    Dr. Paola Perego

  80. Mechanisms Controlling Sensitivity to Platinum Complexes: Role of p53 and DNA Mismatch Repair

    Article • Current Cancer Drug Targets, February 2003, Bentham Science Publishers

    Dr. Paola Perego

  81. Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles

    Article • The Journal of Experimental Medicine, May 2002, Rockefeller University Press

    Dr. Paola Perego

  82. Novel 7-Oxyiminomethyl Derivatives of Camptothecin with Potent in Vitro and in Vivo Antitumor Activity

    Article • Journal of Medicinal Chemistry, September 2001, American Chemical Society (ACS)

    Dr. Paola Perego

  83. Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs

    Article • Biochemical Pharmacology, April 2001, Elsevier

    Dr. Paola Perego

  84. Novel cytotoxic 7-iminomethyl and 7-aminomethyl derivatives of camptothecin

    Article • Bioorganic & Medicinal Chemistry Letters, February 2001, Elsevier

    Dr. Paola Perego

  85. Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy

    Article • Biochemical Pharmacology, February 2001, Elsevier

    Dr. Paola Perego

  86. A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line

    Article • European Journal of Cancer, January 2001, Elsevier

    Dr. Paola Perego

  87. Novel 7-Substituted Camptothecins with Potent Antitumor Activity

    Article • Journal of Medicinal Chemistry, October 2000, American Chemical Society (ACS)

    Dr. Paola Perego

  88. Bcl-2 phosphorylation in a human breast carcinoma xenograft: a common event in response to effective DNA-damaging drugs

    Article • Biochemical Pharmacology, July 2000, Elsevier

    Dr. Paola Perego

  89. Molecular mechanisms of resistance to taxanes and therapeutic implications

    Article • Drug Resistance Updates, December 1999, Elsevier

    Dr. Paola Perego

  90. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts

    Article • British Journal of Cancer, July 1999, Springer Science + Business Media

    Dr. Paola Perego

  91. Ovarian cancer cisplatin-resistant cell lines: Multiple changes including collateral sensitivity to Taxol

    Article • Annals of Oncology, April 1998, Oxford University Press (OUP)

    Dr. Paola Perego

  92. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems

    Article • Cancer Chemotherapy and Pharmacology, February 1998, Springer Science + Business Media

    Dr. Paola Perego

  93. Molecular Mechanisms Controlling Sensitivity to Toxic Metal Ions in Yeast

    Article • Toxicology and Applied Pharmacology, December 1997, Elsevier

    Dr. Paola Perego

  94. Role of apoptotic response in cellular resistance to cytotoxic agents

    Article • Pharmacology & Therapeutics, October 1997, Elsevier

    Dr. Paola Perego

  95. Cisplatin analogues with sulfur donor ligands. (Ethylenediamine)platinum(II) complexes with ligands possessing a sulfinyl or sulfanyl group linked to an anionic oxygen donor atom. Reactivity and cytotoxicity

    Article • Journal of the Chemical Society Dalton Transactions, January 1995, Royal Society of Chemistry

    Dr. Paola Perego

  96. Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types

    Article • Anti-Cancer Drugs, December 1994, Wolters Kluwer Health

    Dr. Paola Perego

  97. Effect of modulation of protein kinase C activity on cisplatin cytotoxicity in cisplatin-resistant and cisplatin-sensitive human osteosarcoma cells

    Article • Cancer Letters, August 1993, Elsevier

    Dr. Paola Perego

  98. The role of glutathione in combination with cisplatin in the treatment of ovarian cancer

    Article • Cancer Treatment Reviews, December 1991, Elsevier

    Dr. Paola Perego

  99. Modulation of epidermal growth factor receptor tyrosine phosphorylation by tumor necrosis factor

    Article • Cancer Letters, May 1991, Elsevier

    Dr. Paola Perego

  100. Genetic Manipulation of Yeast to Identify Genes Involved in Regulation of Chemosensitivity

    Article • Springer Science + Business Media

    Dr. Paola Perego